These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9762687)

  • 1. Body fluid markers to monitor multiple sclerosis: the assays and the challenges.
    Laman JD; Thompson EJ; Kappos L
    Mult Scler; 1998 Jun; 4(3):266-9. PubMed ID: 9762687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological markers in body fluids for activity and progression in multiple sclerosis.
    Sørensen PS
    Mult Scler; 1999 Aug; 5(4):287-90. PubMed ID: 10467390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body fluid markers for course and activity of disease in multiple sclerosis and 3rd European Charcot Foundation Lecture. Madrid, Spain, 2-4 October 1997. Proceedings.
    Mult Scler; 1998 Jun; 4(3):93-269. PubMed ID: 9867426
    [No Abstract]   [Full Text] [Related]  

  • 4. Are there any body fluid markers of brain atrophy in multiple sclerosis?
    Giovannoni G; Green AJ; Thompson EJ
    Mult Scler; 1998 Jun; 4(3):138-42. PubMed ID: 9762663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Free light-chain immunoglobulins in the biological fluids of patients with multiple sclerosis].
    Totolian NA; Griazeva IV; Klimovich VB; Totolian AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(5):34-8. PubMed ID: 9245156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers in multiple sclerosis].
    Fernández Ó; Arroyo-González R; Rodríguez-Antigüedad A; García-Merino JA; Comabella M; Villar LM; Izquierdo G; Tintoré M; Oreja-Guevara C; Álvarez-Cermeño JC; Meca-Lallana JE; Prieto JM; Ramió-Torrentà L; Martínez-Yélamos S; Montalban X
    Rev Neurol; 2013 Apr; 56(7):375-90. PubMed ID: 23520007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.
    Awad A; Hemmer B; Hartung HP; Kieseier B; Bennett JL; Stuve O
    J Neuroimmunol; 2010 Feb; 219(1-2):1-7. PubMed ID: 19782408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body fluid biomarkers for multiple sclerosis--the long road to clinical application.
    Teunissen CE; Malekzadeh A; Leurs C; Bridel C; Killestein J
    Nat Rev Neurol; 2015 Oct; 11(10):585-96. PubMed ID: 26392381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers to confirm diagnosis and monitor the therapy in multiple sclerosis patients.
    Michałowska-Wender G; Losy J; Wender M
    Folia Neuropathol; 2001; 39(1):1-5. PubMed ID: 11678345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin basic protein-like material in the urine of multiple sclerosis patients: relationships to clinical and neuroimaging changes.
    Whitaker JN
    Mult Scler; 1998 Jun; 4(3):243-6. PubMed ID: 9762682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological markers of the inflammatory phase of multiple sclerosis.
    Uccelli A; Pedemonte E; Narciso E; Mancardi G
    Neurol Sci; 2003 Dec; 24 Suppl 5():S271-4. PubMed ID: 14652787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of biological markers in the diagnosis and follow-up of patients with multiple sclerosis. Test of five fluids].
    Oehninger-Gatti C; Buzó R; Alcántara JC; Chouza C; Gómez A; Cibils D; Gordon-Firing S
    Rev Neurol; 2000 May 16-31; 30(10):977-9. PubMed ID: 10919199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathogenesis of multiple sclerosis. Antibody dependent cytotoxicity of lymphocytes against myelin basic proteins in multiple sclerosis].
    Frick E; Stickl H
    Fortschr Med; 1977 Oct; 95(37):2235-41. PubMed ID: 914178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis.
    Lamers KJ; de Reus HP; Jongen PJ
    Mult Scler; 1998 Jun; 4(3):124-6. PubMed ID: 9762659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis--emerging concepts of disease pathogenesis.
    Antel J
    J Neuroimmunol; 1999 Jul; 98(1):45-8. PubMed ID: 10426361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring multiple sclerosis course and activity with TNF-alpha.
    Chofflon M; Fellay B
    Mult Scler; 1998 Jun; 4(3):188-92. PubMed ID: 9762672
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery of highly specific protein markers for the identification of biological stains.
    Legg KM; Powell R; Reisdorph N; Reisdorph R; Danielson PB
    Electrophoresis; 2014 Nov; 35(21-22):3069-78. PubMed ID: 25070728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis.
    Brucklacher-Waldert V; Stuerner K; Kolster M; Wolthausen J; Tolosa E
    Brain; 2009 Dec; 132(Pt 12):3329-41. PubMed ID: 19933767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body fluid biomarkers in multiple sclerosis.
    Comabella M; Montalban X
    Lancet Neurol; 2014 Jan; 13(1):113-26. PubMed ID: 24331797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).
    Fernández Ó; Álvarez-Cermeño JC; Arroyo-González R; Brieva L; Calles-Hernández MC; Casanova-Estruch B; Comabella M; de las Heras V; García-Merino JA; Hernández-Pérez MA; Izquierdo G; Meca-Lallana JE; Muñoz-García D; Olascoaga J; Oreja-Guevara C; Prieto JM; Ramió-Torrentà L; Rodríguez-Antigüedad A; Romero-Pinel L; Sanchez F; Téllez N; Tintoré M; Montalban X;
    Rev Neurol; 2012 Jun; 54(11):677-91. PubMed ID: 22627749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.